Harnessing the Tumor Microenvironment: A New Frontier in Cancer Therapy

Stromal cells Immune cells ECM Blood vessels Cancer Cells T cells Tumor-associated macrophages (TAMs) B cells Tumor-associated neutrophils (TANs) Myeloid-derived suppressor cells (MDSCs) Natural killer (NK) cells Dendritic cells (DCs) Cancer-associated fibroblasts (CAFs) Endothelial cells Adipocytes Pericytes Structural proteins HARNESSING THE TUMOR MICROENVIRONMENT: Written by Mariana Gil, PhD | Designed by Janette Lee-Latour The tumor microenvironment (TME) is a complex system that involves cancer cells, immune cells, stromal cells, blood vessels and extracellular matrix (ECM) components, which are interconnected via several signaling molecules.1 The interaction of these elements modulates tumor growth, metastasis and therapeutic responses.1 Understanding these interactions helps researchers find new and more effective therapeutic targets. This infographic explores the key components of the TME, their roles in cancer progression and how these elements can be leveraged to develop new and better cancer therapies. The TME consists of a complex and dynamic mixture of non-cancerous cells, ECM proteins and signaling molecules that surround the cancer cells forming a tumor.2 A New Frontier in Cancer Therapy TME CORE COMPONENTS The TME is not just a passive backdrop. Instead, it actively drives cancer evolution, immune escape, metastasis and treatment resistance. An intricate network of cytokines, chemokines and growth factors mediates interactions among cancer cells, stromal cells, immune cells, vasculature and the ECM, ultimately determining how cancers grow and respond to therapy.3,4,5 Anti-tumor immune cells T cells, NK cells, B cells M1 TAMs, N1 TANs Pro-tumor immune cells M2 TAMs, N2 TANs Angiogenesis Exhaustion or apoptosis Metabolic disruption (hypoxia, acidosis) HOW THE TME SHAPES CANCER PROGRESSION AND THERAPY RESPONSE Some molecules involved in these interactions are: ECM • Composed of structural proteins (collagens, laminins, fibronectin, proteoglycans) • Provide structural support and influence cell adhesion/migration BLOOD VESSELS • Deliver oxygen and nutrients • Remove waste • Transport immune cells and drugs STROMAL CELLS CAFs • Fibroblasts reprogrammed by cancer cells that support tumor survival • Produce and remodel the ECM • CAF heterogeneity is linked to resistance to therapy Endothelial cells • Form the lining of blood vessels • Create a dysfunctional vasculature limiting the entrance of immune cells, nutrients, oxygen and drugs to the tumor Adipocytes • Release fatty acids, cytokines and growth factors that fuel tumor growth Pericytes • Provide structural support to blood vessels within the TME • Modulate the tumor vasculature stability • Lack of pericytes is correlated with poor prognosis IMMUNE CELLS T cells Different types of T cells are found within and surrounding the tumor: • CD8+ cytotoxic T cells directly kill tumor cells when activated • CD4+ helper T cells coordinate immune responses • Regulatory T cells suppress immune activity TAMs • M1 TAMs have anti-tumor functions • M2 TAMs have been reprogrammed by cancer cells to support cancer progression B cells • Produce antibodies and present antigens to T cells • Can support or inhibit tumor growth depending on subtype TANs • N1 TANs have anti-tumor functions • N2 TANs have been reprogrammed by cancer cells to support cancer progression MDSCs • Heterogeneous group of immature myeloid cells that suppress T-cell and NK-cell function • High levels correlate with poorer therapy response NK cells • Typically found outside of the tumor • Kill abnormal cells without prior activation • Their presence in some cancers correlates with good prognosis DCs • Activate T cells by presenting tumor antigens • Often dysfunctional in tumors Stromal cells CAFs Endothelial cell Tumor cells PD-1/PD-L1 axis (programmed death-1/programmed death-ligand 1) • PD-L1 (which is upregulated in tumor, stromal and some immune cells) binds to PD-1 (receptor on activated T cells), promoting T-cell exhaustion and apoptosis IMMUNE CHECKPOINTS IL-1, IL-6, IL-10 (interleukins) | TNF-α (tumor necrosis factor-α) • Regulate immune activation, inflammation, differentiation, survival and cell trafficking CSF-1 (colony stimulating factor-1) • Promotes recruitment and polarization of TAMs towards the pro-tumor M2 phenotype CYTOKINES (Produced by immune, stromal and tumor cells) VEGF (vascular endothelial growth factor) • Promotes angiogenesis TGF-β (transforming growth factor-β) • Drives immunosuppression and ECM remodeling GROWTH FACTORS (Produced by immune, stromal and tumor cells) HIFs (hypoxia-inducible factors) • Adapt tumor cells to low oxygen, promoting angiogenesis and metabolic reprogramming SIGNALING PATHWAYS MMPs (matrix metalloproteinases) • Degrade ECM components, promote invasion, metastasis and therapy resistance PROTEOLYTIC ENZYMES (Produced by immune, stromal and tumor cells) ECM Immunesystem Vasculature Metabolic conditions • Inhibition of TAMs recruitment and polarization (CSF-1 inhibitors) • Inhibition of inflammation or pro-tumorigenic factors (anti IL-1) • Checkpoint inhibitors (anti-PD-1) • HIF-1 inhibitors (topoisomerase 1 inhibitor) • Proton exchangers and transporters inhibitors • Hypoxia-activated prodrugs (HAPs): small molecules that become cytotoxic in hypoxic tissues (tirapazamine) • Drugs that reduce the secretion of ECM proteins (Angiotensin II receptor agonists) • MMPs inhibitors (CMT-3, COL-3) • Fibroblast inhibition (TGF-β inhibitors) • Inhibition of VEGF (bevacizumab) Many modern cancer therapies work by reprogramming the TME. This involves restoring immune activity, normalizing blood vessels, reducing stromal barriers and disrupting immunosuppressive signaling.6,7 Some of the TME targets and associated drugs are: THERAPEUTIC STRATEGIES TO HARNESS THE TME pH O2 REFERENCES 1. Guven H, Székely Z. Leveraging the tumor microenvironment as a target for cancer therapeutics: a review of emerging opportunities. Pharmaceutics. 2025;17(8):980. doi: 10.3390/ pharmaceutics17080980 2. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–R925. doi: 10.1016/j.cub.2020.06.081 3. Wang Q, Shao X, Zhang Y, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149–11165. doi: 10.1002/cam4.5698 4. Dzobo K, Senthebane DA, Dandara C. The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers. 2023;15(2):376. doi: 10.3390/cancers15020376 5. Verma NK, Wong BHS, Poh ZS, et al. Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine. 2022;83:104216. doi: 10.1016/j.ebiom.2022.104216 6. Benavente S, Sánchez-García A, Naches S, LLeonart ME, Lorente J. Therapy-induced modulation of the tumor microenvironment: new opportunities for cancer therapies. Front Oncol. 2020;10:582884. doi: 10.3389/fonc.2020.582884 7. Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. doi: 10.3390/ijms20040840 Harnessing the TME can transform cancer treatment by turning the tumor’s own ecosystem into a therapeutic opportunity. Restore the immune response toward cancer cells Reduce physical barriers to therapy and minimize invasiveness Enhance immune responses and sensitize tumors to therapy Avoid neovascularization, enhance drug delivery and immune infiltration Abnormal vasculature Abnormal vasculature Radiation Radiation Tumor growth and survival Immunotherapy Chemotherapy Immunosuppression Dense and stiff ECM ECM remodeling Metastasis Enhancement Impairment